CO-ARROW-ELECTRONICS
1.9.2020 18:02:16 CEST | Business Wire | Press release
Global technology provider Arrow Electronics, Inc. (NYSE:ARW) today announced that Norwegian telecoms provider Telenor has chosen ArrowSphere as its strategic multi-cloud brokerage platform. Working with Arrow, Telenor can manage a unique catalogue of cloud offerings via ArrowSphere including IaaS, PaaS and SaaS solutions, and is initially delivering Microsoft 365, IBM MaaS360 and 7P MDM to both channel customers and end users in Norway, Sweden and Denmark.
ArrowSphere offers Telenor the potential to generate new revenue streams through the delivery of cloud offerings for small and medium enterprises (SMEs). ArrowSphere will provide key growth opportunities for Telenor, such as new services in the field of AI and IoT solutions. Telenor will be able to onboard its own offers and software solutions within the cloud services catalogue.
“Telenor is an early adopter within the telco industry and has recognised the benefits of integrated cloud-services via ArrowSphere for both channel customers and end users. ArrowSphere provides a cost-effective, low maintenance way of delivering value-added software and applications that help small to medium-sized businesses scale-up,” said Henrik Resting-Jeppesen, vice president of Arrow’s enterprise computing solutions business, Nordics and Eastern Europe. “The cloud brokerage platform is a critical part of Telenor’s cloud strategy to automate the provisioning of cloud solutions and the management of its customers. ArrowSphere’s flexibility, scalability and deep integration possibilities have been key to reach Telenor’s expectations and build the infrastructure that will support Telenor’s cloud growth.”
“ArrowSphere offers Telenor a stable, cost-efficient method for delivering software applications hosted in the cloud to our resellers and customers, and enables us to provide SMEs with the solutions they want to scale their business, delivered by a trusted telecoms provider,” said Stian Alapnes, platform advisor, Telenor Norway. “Our customers get the software they need seamlessly which means that working with Arrow has been easy. Across the Nordic region we have strongly increased subscriptions for ArrowSphere since we started, and we are looking forward to our future business with Arrow which will see additional products and solutions.”
ArrowSphere enables the channel with a fast and efficient way to quote, order, manage, analyse and invoice a wide variety of cloud solutions. With its enhanced user experience and functionalities, the platform has been engineered to streamline the connection between cloud service providers and end customers. A dedicated ArrowSphere team helps customers manage the entire workflow and supports channel customers in building and growing their cloud practice.
About Arrow Electronics
Arrow Electronics guides innovation forward for over 175,000 leading technology manufacturers and service providers. With 2019 sales of $29 billion, Arrow develops technology solutions that improve business and daily life. Learn more at fiveyearsout.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200901005802/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Debiopharm’s Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistance14.10.2026 14:00:00 CEST | Press release
Despite the remarkable progress made by ADCs, many cancer patients continue to face disease progression due to treatment resistance, tumor heterogeneity, and dose-limiting toxicities At World ADC 2026 San Diego, Debiopharm presented their latest ADC innovation to overcome these challenges with novel linker-payload technology, including modular dual payload linker MLINK DUO and modular cathepsin B-cleavable linker MLINK Select Research results with various MultiLINKTM Linker Technologies showcased broadening of vedotin-based ADC therapeutic index for MLINK Select ADCs, synergistic antitumor activity with MLINK Duo, and homogeneous DAR8 conjugation with MLINK HiSol Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced their latest research on antibody drug conjugate (ADC) research released at World ADC San Diego 2026. Results highlighted the pre-cli
Responsible AI for Children: IEEE Delivers a Trusted Safety Formula to Help Protect Kids Online14.10.2026 14:00:00 CEST | Press release
With children’s AI exposure surging, IEEE Standards Association certification helps ensure AI products for kids are ethically designed, independently tested and continually accountable for safety and well-beingFirst product certification issued to educational platform from Greek National Centre for Scientific Research The IEEE Standards Association, the global, consensus-building standards development organization of IEEE – the world’s largest technical professional organization and public charity dedicated to advancing technology for the benefit of humanity – today advanced its Responsible AI for Children (RAIC) Certification Program with the first product certified for children’s online safety. As children increasingly engage with digital and AI-enabled technologies, parents, educators, developers, and regulators want tools they can trust. IEEE’s Responsible AI for Children (RAIC) certification directly addresses these needs by translating global technical standards into a practical
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 202614.10.2026 14:00:00 CEST | Press release
− TAK-881 met its primary endpoint, demonstrating pharmacokinetic comparability to HYQVIA® in patients 16 years and older − TAK-881 may shorten infusion times and offer the opportunity for fewer required infusion sites compared to HYQVIA with 50% less volume while maintaining up to once-monthly dosing − Adult infection outcomes and safety and tolerability profiles were comparable to HYQVIA based on descriptive analyses and consistent with established IG therapy standards Takeda (TSE:4502/NYSE:TAK) announced detailed results from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) and Recombinant Human Hyaluronidase], which, if approved, has the potential to become the first facilitated SCIG 20% therapy for patients with Primary Immunodeficiency Disease (PID) administered up to once-monthly (every 3 to 4 weeks). Data in participants aged 16 years and older are featured in two late-b
Datavault AI Appoints Shareholder and Investment Executive Jeffrey Tirman to the Boardof Directors14.10.2026 13:55:00 CEST | Press release
Tirman, through his family office Abri Capital Ltd., holds 26 million DVLT shares and brings over 35 years of international investment management and corporate restructuring experience to the Company Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced the appointment of Jeffrey Tirman to its Board of Directors, effective as of October 12, 2026. Mr. Tirman was designated by NYIAX, Inc. (“NYIAX”) in connection with Datavault AI's recently completed acquisition of NYIAX, and he previously served on NYIAX's board of directors. As a Datavault AI Shareholder, Mr. Tirman brings both an ownership perspective and extensive management experience to the Board. Mr. Tirman has more than 35 years of international investment management experience, focused on corporate transformation, capital strategy and value creation. He has led c
EZO Reaches Financial Close on €150 Million Senior Debt Facility14.10.2026 13:21:00 CEST | Press release
Investment-grade, non-recourse financing will support the delivery of more than 3,000 charge points primarily across the whole of the UK along with additional development in Ireland. EZO has reached financial close on a €150 million investment-grade, non-recourse, senior debt facility. The funding will finance the design, installation, operation and maintenance of over 3,000 charge points, representing over 100,000 kWs of capacity, across the UK and Ireland under mostly long-term public sector “PPP-like” concessions with an attractive risk allocation between the public and private sector that will significantly advance EV infrastructure delivery, on time and to budget. These charge points are estimated to generate well in excess of £1 billion in electricity sales over the next 20 years, a portion of which will be shared with the public sector while, at the end of the concession, the chargers will revert back to the public sector. Headquartered in Ireland, EZO has expanded rapidly into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom